Research publications

Alfred Health research outcomes are published in a wide range of peer reviewed journals. 

Search or browse research publications by year, research area, publication type or keyword.

Clear filter
Publication Details
Different brain networks underlying intelligence in autism spectrum disorders

Pua, EPK, Malpas, CB, Bowden, SC, Seal, ML

(2018), Hum Brain Mapp, 39, 3253-3262

DOI: 10.1002/hbm.24074

Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium

Kong XZ, Mathias SR, Guadalupe T; ENIGMA Laterality Working Group, Glahn DC, Franke B, Crivello F, Tzourio-Mazoyer N, Fisher SE, Thompson PM, Francks C

(2018), Proc Natl Acad Sci USA, 115(22), e5154-5163

DOI: 10.1073/pnas.1718418115

Development of white matter fibre density and morphology over childhood: A longitudinal fixel-based analysis

Genc S, Smith RE, Malpas CB, Anderson V, Nicholson JM, Efron D, Sciberras E, Seal ML, Silk TJ

(2018), Neuroimage, 183, 666-676

DOI: 10.1016/j.neuroimage.2018.08.043

The benefits of adding metformin to tamoxifen to protect the endometrium-A randomized placebo-controlled trial

Davis SR, Robinson PJ, Jane F, White S, Brown KA, Piessens S, Edwards A, McNeilage J, Woinarski J, Chipman M, Bell RJ

(2018), Clin Endocrinol, 89(5), 605-612

DOI: 10.1111/cen.13830

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma

Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu S, McArthur GA, McCormack CJ, Henderson M, Hicks RJ, Shackleton M

(2018), Ann Oncol, 29(7), 1569-1574

DOI: 10.1093/annonc/mdy124

Immunotherapy induced pyrexia and the role of PET/CT

McLean L, Soon JA, Haydon A

(2018), Int J Case Rep, 2, 29

DOI: 10.28933/ijcr-2018-06-2901

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Maio M, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan P, Ibrahim N, Marreaud S, van Akkooi ACJ, Suciu S, Robert C

(2018), N Engl J Med, 378(19), 1789-1801

DOI: 10.1056/NEJMoa1802357

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy

Adler NR, Wolfe R, McArthur GA, Kelly JW, Haydon A, McLean CA, Mar VJ

(2018), Br J Cancer, 118(10), 1289-1295

DOI: 10.1038/s41416-018-0088-8

Concordance of somatic mutational profile in multiple primary melanomas

Adler NR, McLean CA, Wolfe R, Kelly JW, McArthur GA, Haydon A, Tra T, Cummings N, Mar VJ

(2018), Pigment Cell Melanoma Res, 31(5), 592-603

DOI: 10.1111/pcmr.12702

3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial

Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Paul J

(2018), Lancet Oncol, 19(4), 562-578

DOI: 10.1016/S1470-2045(18)30093-7

Immunohistochemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres

Grant M, Haydon A, Au L, Wilkins S, Oliva K, Segelov E, Antill Y, Carne P, Ranchod P, Polglase A, Farmer C, Chin M, Wale R, Simpson P, Bell S, Skinner S, McMurrick P, Shapiro J

(2018), Int J Surg, 51, 71-75

DOI: 10.1016/j.ijsu.2018.01.020

Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors

Ameratunga M, Ch»nard-Poirier M, Moreno Candilejo I, Pedregal M, Lui A, Dolling D, Aversa C, Ingles Garces A, Ang JE, Banerji U, Kaye S, Gan H, Doger B, Moreno V, de Bono J, Lopez J

(2018), Eur J Cancer, 89, 56-63

DOI: 10.1016/j.ejca.2017.11.012

Anti-angiogenic therapy for high-grade glioma

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M

(2018), Cochrane Database Syst Rev, 11, CD008218

DOI: 10.1002/14651858.CD008218.pub4

Clinical Outcome of Patients with Advanced Biliary Tract Cancer in a Dedicated Phase I Unit

Sundar R, Custodio A, Petruckevich A, Ch»nard-Poirier M, Ameratunga M, Collins D, Lim J, Kaye SB, Tunariu N, Banerji U, de Bono J, Lopez J

(2018), Clin Oncol, 30(3), 185-191

DOI: 10.1016/j.clon.2017.11.011

Personalized cancer immunotherapy: Today's challenge and tomorrow's promise

Ameratunga M, Xu W, Lopez J

(2018), J Immunother Precis Oncol, 1, 56-67

DOI: 10.4103/JIPO.JIPO_13_18

CNS cancer immunity cycle and strategies to target this for glioblastoma

Ameratunga M, Coleman N, Welsh L, Saran F, Lopez J

(2018), Oncotarget, 9(32), 22802-22816

DOI: 10.18632/oncotarget.24896

Clinical outcomes of adolescents and young adults with advanced solid tumours participating in phase I trials

Sundar R, McVeigh T, Dolling D, Petruckevitch A, Diamantis N, Ang JE, Chenard-Poiri»r M, Collins D, Lim J, Ameratunga M, Khan K, Kaye SB, Banerji U, Lopez J, George AJ, de Bono JS, van der Graaf WT

(2018), Eur J Cancer, 101, 55-61

DOI: 10.1016/j.ejca.2018.06.003

A single-institution prospective evaluation of a neuro-oncology multidisciplinary team meeting

Ameratunga M, Miller D, Ng W, Wada M, Gonzalvo A, Cher L, Gan HK

(2018), J Clin Neurosci, 56, 127-130

DOI: 10.1016/j.jocn.2018.06.032

A study of 1088 consecutive cases of electrolyte abnormalities in oncology phase I trials

Ingles Garces AH, Ang JE, Ameratunga M, Ch»nard-Poirier M, Dolling D, Diamantis N, Seeramreddi S, Sundar R, de Bono J, Lopez J, Banerji U

(2018), Eur J Cancer, 104, 32-38

DOI: 10.1016/j.ejca.2018.08.019

The value of participating in clinical trials: the whole is greater than the sum of its parts

Zalcberg JR, Friedlander M

(2018), Med J Aust, 209(10), 424-425

DOI: 10.5694/mja17.01266

285 286 287 288 289